# Walgreens Boots Alliance

Type: Company (WBA)

Source: GetYourBrief — https://getyourbrief.com/entity/walgreens-boots-alliance
Canonical HTML page: https://getyourbrief.com/entity/walgreens-boots-alliance

## Timeline

- **2024-06-13**: SCOTUS Ruling — Supreme Court dismisses challenge to mifepristone access on standing grounds, preserving status quo.
- **2024-06**: Supreme Court Ruling — SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
- **2024-03-01**: Retail Pharmacy Entry — Major chains CVS and Walgreens receive certification to dispense abortion pills.
- **2023-01**: Pharmacy Certification — FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
- **2022-06-24**: Dobbs Decision — Supreme Court overturns Roe v. Wade, leading to state-level bans.
- **2021-12-16**: Telehealth Expansion — FDA permanently removes in-person dispensing requirements, allowing mail-order access.
- **2021-12**: Mail-Order Authorization — FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
- **2016-03**: Protocol Expansion — FDA extends usage window to 10 weeks and reduces required office visits from three to one.
- **2000-09-28**: Initial FDA Approval — FDA approves Mifepristone for medical termination of early pregnancy.
- **2000-09**: Initial FDA Approval — FDA approves mifepristone for medical termination of pregnancy through seven weeks.

## Recent coverage (6 stories, network-wide)

### Over 500 Tylenol suits revived: Prenatal care guidelines under microscope
2026-07-25 19:57:02 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
Full story: https://gethealthbrief.com/story/tylenol-autism-lawsuits-revived-health

### 500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma
2026-07-25 19:56:51 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Full story: https://getbiobrief.com/story/tylenol-autism-lawsuits-revived-bio

### Medication Abortion Becomes Primary Method Amid Escalating Regulatory Warfare
2026-03-24 07:42:54 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
Full story: https://gethealthbrief.com/story/medication-abortion-regulation-trends-2026

### Medication Abortion Dominates US Landscape Amid Escalating Legal Challenges
2026-03-24 07:42:49 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion now accounts for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and state shield laws. This shift has triggered a wave of regulatory counter-measures from opponents, focusing on the Comstock Act and FDA approval processes.
Full story: https://getlegalbrief.com/story/medication-abortion-regulation-legal-tech-trends

### Healthcare Divergence: GLP-1 Leaders Dominate Quant Ratings Post-Earnings
2026-03-14 15:21:35 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seeking Alpha's post-earnings quant analysis reveals a stark divide in the healthcare sector, with innovation-driven biopharma stocks significantly outperforming retail pharmacy and managed care. The ratings highlight a shift in investor preference toward high-growth obesity and specialty medicine franchises over traditional defensive value plays.
Full story: https://getbiobrief.com/story/healthcare-quant-ratings-post-earnings-2026

### Post-Earnings Quant Ratings Reveal Sharp Divide in Healthcare Performance
2026-03-14 15:19:30 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Following the latest earnings cycle, Seeking Alpha's quantitative analysis identifies a significant performance gap between biopharma innovators and retail pharmacy giants. While Incyte and UnitedHealth lead with near-perfect scores, Walgreens and Moderna have fallen into 'Strong Sell' territory.
Full story: https://gethealthbrief.com/story/healthcare-quant-ratings-earnings-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.